InterpretOmics, India’s first Genomic Data Sciences Company, has announced that it has opened a next generation sequencing (NGS) facility at Bengaluru. The state of the art facility, set up at a cost of Rs. 35 million, is to offer genome sequencing services spanning to R&D institutes, pharmaceuticals, biotechnology firms, and clinical research organisations (CROs).

The primary activities in this new facility would be biomarker discovery, drug target discovery, and trial stratification for biotech, pharma and CROs and genomics.

“The opening of this state of the art facility will go a long way in providing quality services and determining company’s success moving forward,” said Dr. Rajeev Soni, senior manager, research amd development, Novozymes South Asia Pvt. Ltd.

The Bengaluru-based company is dedicated to the discovery of novel and innovative approaches to the treatment of complex diseases. It provides on-premise and SaaS enterprise-grade software platform for research organisations, pharmaceuticals, biotechnology firms and hospitals to analyse genetic information and identify biomarkers critical to the development of targeted drugs and therapies. The company’s solution helps pharmaceuticals, biotechs and CROs reduce the cost of R&D, improve time to discovery and market and increase return on R&D investments.

“The newly inaugurated centre will cater to our growing customer base in next generation sequencing and analysis. The facility also houses a bio-bank,” said Prahalad Achutharao, co-founder & chief executive officer, InterpretOmics.

“The focus is on research, development and delivering model (RDD). Our USP is carrying out R&D along with the delivery. InterpretOmics now has 35 professionals and plans to achieve a head count of 40 by the end of July 2015,” he added.

“Data Scientists at InterpretOmics are experts in analysing vast amount of genomic data. Our team has handled numerous complex next generation sequencing data analysis projects and processed more than 250 TB of data. With our new Centre for Next Generation Sequencing, we will offer both – sequencing, analysis and interpretation services and thus create comfort, convenience and credibility to our NGS clientele from industry,” said Dr. Asoke Talukder, co-founder & chief scientific officer, InterpretOmics.